Alzamend Neuro, Inc. (ALZN)
NASDAQ: ALZN · Real-Time Price · USD
0.9509
-0.1091 (-10.29%)
Mar 31, 2025, 2:21 PM EDT - Market open

Company Description

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders.

Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease.

The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001.

Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Alzamend Neuro, Inc.
Alzamend Neuro logo
Country United States
Founded 2016
IPO Date Jun 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Stephan Jackman

Contact Details

Address:
3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, Georgia 30326
United States
Phone 844 722 6333
Website alzamend.com

Stock Details

Ticker Symbol ALZN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year May - April
Reporting Currency USD
IPO Price $5.00
CIK Code 0001677077
CUSIP Number 02262M308
ISIN Number US02262M4078
Employer ID 81-1822909
SIC Code 2834

Key Executives

Name Position
Stephan Jackman Chief Executive Officer and Director
Milton Charles Ault III Founder and Vice Chairman
David J. Katzoff Chief Financial Officer
Henry C. W. Nisser Esq. Executive Vice President, General Counsel and Director

Latest SEC Filings

Date Type Title
Mar 27, 2025 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 19, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 17, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 13, 2025 DEF 14A Other definitive proxy statements
Mar 13, 2025 S-3 Registration statement under Securities Act of 1933
Mar 10, 2025 10-Q Quarterly Report
Mar 3, 2025 8-K Current Report
Feb 28, 2025 PRE 14A Other preliminary proxy statements
Feb 28, 2025 8-K Current Report
Dec 12, 2024 8-K Current Report